We are live on
!
Find out more
FCMV
Foresite Capital Management V Portfolio holdings
AUM
$271M
1-Year Est. Return
309.87%
This Fund
S&P 500
This Quarter
Est. Return
+13.7%
1 Year Est. Return
+309.87%
3 Year Est. Return
+356.88%
5 Year Est. Return
+250.56%
10 Year Est. Return
–
AUM
$129M
AUM Growth
-$1.31M
(-1%)
Cap. Flow
+$4.73M
Cap. Flow
% of AUM
3.68%
Top 10 Holdings %
Top 10 Hldgs %
99.7%
Holding
14
New
–
Increased
4
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$8.08M |
| 2 |
Hims & Hers Health
HIMS
|
+$4.11M |
| 3 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$1.46M |
| 4 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
+$808K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invivyd
IVVD
|
+$4.48M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$2.19M |
| 3 |
Adicet Bio
ACET
|
+$1.89M |
| 4 |
ME
23andMe Holding Co
ME
|
+$1.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Hims & Hers Health
HIMS
$6.26B
| $25.9M | 20.12% |
4,041,383
+721,597
| +22% | +$4.11M |
|
2
Compass Therapeutics
CMPX
$349M
| $22.1M | 17.19% |
4,400,000
| – | – |
|
3
Aclaris Therapeutics
ACRS
$743M
| $19.8M | 15.39% |
1,258,243
| – | – |
|
|
THRX
4
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $17.9M | 13.87% |
3,585,346
+250,000
| +7% | +$1.46M |
|
|
PRDS
5
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $17M | 13.18% |
10,037,935
+637,420
| +7% | +$808K |
|
|
SLGC
6
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $8.83M | 6.86% |
3,516,472
| – | – |
|
|
KNTE
7
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $5.34M | 4.15% |
875,001
| – | – |
|
|
8
Adicet Bio
ACET
$84.7M
| $4.99M | 3.88% |
34,915
-7,585
| -18% | -$1.89M |
|
|
9
Disc Medicine
IRON
$3.03B
| $4.84M | 3.76% |
243,513
+162,342
| +200% | +$8.08M |
|
10
Quantum-Si Incorporated
QSI
$157M
| $1.69M | 1.31% |
924,379
| – | – |
|
11
Pharvaris
PHVS
$2.37B
| $384K | 0.3% |
34,142
| – | – |
|
|
12
Enanta Pharmaceuticals
ENTA
$378M
| – | – |
-42,250
| Closed | -$2.19M |
|
|
13
Invivyd
IVVD
$171M
| – | – |
-1,431,826
| Closed | -$4.48M |
|
|
ME
14
DELISTED
23andMe Holding Co
ME
| – | – |
-20,346
| Closed | -$1.16M |
|
Similar funds
MAM
MLM
MCM
RP
PCM
S
VW
TP
Foresite Capital Management V's Q4 2022 Portfolio in Review
As of Q4 2022, Foresite Capital Management V held 14 positions worth $129M, down 1% from $130M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Management V deployed $4.73M of net new capital in Q4 2022, adding to 4 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Adicet Bio, an estimated $1.89M trimmed.
- Foresite Capital Management V added most to Disc Medicine in Q4 2022, an estimated $8.08M increase.
- Foresite Capital Management V's biggest Q4 2022 reduction was Adicet Bio, cutting an estimated $1.89M.
- Foresite Capital Management V fully exited Invivyd in Q4 2022, selling an estimated $4.48M.
- Foresite Capital Management V's ten largest holdings make up 100% of its $129M portfolio in Q4 2022.
- Foresite Capital Management V opened 0 new positions and closed 3 in Q4 2022.
- Foresite Capital Management V's portfolio value fell 1% quarter-over-quarter to $129M.
Based on Foresite Capital Management V's 13F filing for Q4 2022, filed 13 Feb 2023.